BioSpace News Archive

Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the appointment of Jeffrey W. Sherman, M.D., F.A.C.P. to the Company’s Board of Directors, effective today.

Terns Pharmaceuticals, Inc. announced that it has granted as of October 1, 2023 equity inducement awards to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan.

89bio, Inc. announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 116,000 shares of the Company’s common stock to four new employees on the later of September 28, 2023 and the employee’s commencement of employment with the Company.

Cytokinetics, Incorporated announced that on September 29, 2023 it granted stock options to purchase an aggregate of 5,700 shares of common stock to two new employees, whose employment commenced in September 2023, as a material inducement to their employment.

Vor Bio announced that, effective as of October 1, 2023, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 19,250 shares of Vor Bio’s common stock and restricted stock units representing the right to receive an aggregate of 28,876 shares of Vor Bio’s common stock to five newly hired employees.

Aadi Bioscience, Inc. announced that an equity award has been granted to its new President and Chief Executive Officer, Dave Lennon, Ph.D., on October 2, 2023, the first date of his employment, in accordance with the Aadi Bioscience, Inc. 2023 Inducement Plan.

A quarter century ago, in September 1998, Gladstone Institutes launched the Gladstone Institute of Neurological Disease.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today presented longer-term data on patients dosed in Parts A and B of its Phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated islet cell therapy in people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemic events (SHEs).

The U.S. Food and Drug Administration has granted approval for EntroGen’s CRCdx® RAS Mutation Detection Kit as a companion diagnostic for Vectibix®, a targeted therapy used in the treatment of colorectal cancer.

A healthy immune system is what defends the body from invaders like bacteria and viruses.